- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03767595
Étude post-approbation ProACT
Étude post-approbation de la thérapie de continence réglable ProACT™ pour hommes
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Matt Kelly, PhD
- Numéro de téléphone: 6124698882
- E-mail: usmtk@coloplast.com
Sauvegarde des contacts de l'étude
- Nom: Lisa DRAPER
- E-mail: usldr@coloplast.com
Lieux d'étude
-
-
California
-
Los Angeles, California, États-Unis, 90033
- Recrutement
- University of Southern California
-
Contact:
- Julissa Morales
- E-mail: julissa.morales@med.usc.edu
-
Chercheur principal:
- Jeffrey Loh-Doyle, MD
-
Santa Barbara, California, États-Unis, 93110
- Recrutement
- Sutter Health
-
Contact:
- Morgan Caldwell-Holden
- E-mail: morgan.caldwell-holden@sutterhealth.org
-
Contact:
- Megan Martinez
- E-mail: megan.martinez@sutterhealth.org
-
Chercheur principal:
- Scott Tobis, MD
-
-
Colorado
-
Denver, Colorado, États-Unis, 80045
- Recrutement
- University of Colorado
-
Contact:
- Andrea Pina
- E-mail: andrea.pinalimones@cuanschutz.edu
-
Chercheur principal:
- Brian Flynn, MD
-
Sous-enquêteur:
- Nate Coddington, MD
-
-
Florida
-
Gainesville, Florida, États-Unis, 32610
- Recrutement
- University of Florida
-
Contact:
- John Marks, DHSc, CCRP
- Numéro de téléphone: 352-273-5618
- E-mail: John.Marks@urology.ufl.edu
-
Chercheur principal:
- Lawrence Yeung, MD
-
Hialeah, Florida, États-Unis, 33016
- Recrutement
- Urological Research Network Corp
-
Chercheur principal:
- Edward Gheiler, MD
-
Contact:
- Isabel Lopez
- E-mail: isabel@besturology.net
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory University
-
Chercheur principal:
- Lindsey Hartsell, MD
-
Contact:
- Nahir Imtiaz
- E-mail: sbimtia@emory.edu
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66103
- Recrutement
- University of Kansas Medical Center
-
Contact:
- Kirk Redger, MD
- Numéro de téléphone: 913-588-1227
- E-mail: kredger@kumc.edu
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- University of Michigan
-
Contact:
- Nailah Henry
- E-mail: hnailah@med.umich.edu
-
Chercheur principal:
- Bahaa Malaeb, MD
-
-
Minnesota
-
Saint Cloud, Minnesota, États-Unis, 56303
- Recrutement
- CentraCare- St. Cloud
-
Contact:
- Andrew Windsperger, MD
- Numéro de téléphone: 320-229-4547
- E-mail: andrew.windsperger@centracare.com
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68124
- Recrutement
- CHI Health Research
-
Chercheur principal:
- Michael Feloney, MD
-
Contact:
- Jan Mitchell
- E-mail: jan.mitchell@commonspirit.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Recrutement
- Lehigh Valley Health Network
-
Contact:
- Megan McGonagle, MSN, RN, PCCN
- E-mail: Megan.mcgonagle@jefferson.edu
-
Chercheur principal:
- Matthew Loecher, MD
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Recrutement
- Allegheny Health Network
-
Contact:
- Rachel Reading
- E-mail: rachel.reading@ahn.org
-
Contact:
- Tibetha Santucci
- E-mail: tibetha.santucci@ahn.org
-
Chercheur principal:
- Kiran Sury, MD
-
-
Texas
-
Arlington, Texas, États-Unis, 76017
- Recrutement
- Urology Partners of North Texas Research Institute
-
Chercheur principal:
- Keith Xavier, MD
-
Contact:
- Grace Yoon
- E-mail: gyoon@folioclinicalresearch.com
-
McAllen, Texas, États-Unis, 78504
- Recrutement
- DHR Health Institute for Research and Development
-
Chercheur principal:
- Henry Ruiz, MD
-
Contact:
- Clarisa Medina
- E-mail: c.medina@dhrhealth.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Subject is a male of at least 50 years of age.
-
Subject demonstrates stress urinary incontinence.
-
Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
-
Subject is willing and able to undergo surgical implantation of ProACT devices.
-
Subject is willing and able to comply with study-required
follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.
-
Subject is willing and able to sign the approved informed consent.
-
Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
-
Subject has a negative urine culture.
-
Subject has no known urogenital malignancy, other than previously treated prostate cancer.
-
Subject meets ONE of the following criteria:
- Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
- Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
-
Physician determines subject to be a suitable surgical candidate.
Exclusion Criteria:
- Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
- Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
- Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
- Subject has undergone radiation therapy in the prostatic area within the last 12 months.
- Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
- Subject has an atonic bladder.
- Subject had, presently has, or is suspected of having bladder cancer.
- Subject has untreated or unsuccessfully treated bladder stones.
- Subject has detrusor sphincter dyssynergia.
- Subject has known hemophilia or a bleeding disorder.
- Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
- Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: ProACT Adjustable Continence Therapy for Men
Patients implanted with ProACT Adjustable Continence Therapy for Men |
The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Urethral Strictures
Délai: 5 years
|
Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up. |
5 years
|
|
Device Erosions
Délai: 5 years
|
Cumulative incidence of ProACT device erosions over 5 years of follow-up. |
5 years
|
|
Incontinence Quality of Life Questionnaire (I-QoL)
Délai: 5 years
|
Results on Validated Incontinence Quality of Life Questionnaire |
5 years
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Effect of ProACT on Subsequent Stress Urinary Incontinence(SUI) Therapy
Délai: 5 years
|
This data will be collected with a "Post ProACT Explant Subsequent Therapy Questionnaire". This questionnaire will ask 3 questions regarding the ProACT therapy
The scale for each question is 0-1. 0 Meaning no effect (a "No" response on the questionnaire) and 1 being some effect ("Yes" response on the questionnaire). No effect (0) on subsequent SUI therapies is the better outcome. |
5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Philip Johnson, PhD, Uromedica, Inc. / Coloplast, Corp
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Troubles urinaires
- Symptômes des voies urinaires inférieures
- Manifestations urologiques
- Incontinence urinaire
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Incontinence urinaire, Stress
Autres numéros d'identification d'étude
- PAS001
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .